Q4 revenues grew 6.1% YoY to | 1280 crore with strong growth in RoW formulations and API segment being partly offset by 17.7% YoY decline in US sales to | 475 crore. Domestic formulations grew 4.7% YoY to | 358 crore. RoW sales grew a robust 76.5% YoY to | 233 crore whereas API segment grew 38.1% YoY to | 214 crore. EBITDA margins declined 45 bps YoY to 26.7% with lower gross margins being mostly offset by lower...